Drug discovery tools · Spatial and functional genomics
Biocartesian
A two person, YC-backed lab service that turns tissue and cell samples into what it calls digital molecular maps. Since its 2024 launch the company has narrowed its pitch to a single proprietary readout, ARADIA, built on RNA imaging chemistry one of its founders developed in graduate school.
Ship us your sample
Biocartesian's pitch to a discovery scientist is simple to state: package a tissue section or a plate of cells, send it to the company's lab, and get back a picture of the molecules inside that no ordinary microscope could resolve. In its 2024 Y Combinator launch post, the company put it this way. "To use our technology, scientists simply ship their biological specimens to our laboratory, where we automate their conversion into digital molecular maps."
By 2026 that idea had sharpened into a specific product. The company's website now centers on a single named technology, ARADIA, the Amplified Random Access DNA Imaging Assay. The pitch has moved from a broad claim about seeing every molecule in a tissue to a narrower, more mechanistic one: sequencing a genetic barcode directly inside a cell, in place, so that a CRISPR guide or an engineered marker can be tied back to whatever a microscope saw happen to that same cell.
The problem it names
Biocartesian's own framing of the gap has not changed much even as the product has. "Most diseases remain a mystery because existing methods can see less than 1% of the molecules within a biological specimen," the company said at launch. Traditional pooled genetic screens, the kind that sort cells by a fluorescent marker or by survival, can scale to thousands of perturbations but only catch phenotypes simple enough to gate on. Arrayed, image-based screens catch richer phenotypes but usually top out at far fewer perturbations because each one runs in its own well. Biocartesian's ARADIA is built to sit between those two approaches: pool the perturbations, then read the identity of each one back out of the same image used to measure the cell's behavior.
Whether that combination changes outcomes for a drug discovery program is not something any public record answers yet. No FDA filing, registered clinical trial, NIH award or NSF award tied to Biocartesian turned up in a search of those federal databases as of September 2026.
Two UPenn PhDs
Ian Dardani and Jessica Li met as PhD students at the University of Pennsylvania. Dardani earned a doctorate in bioengineering there, defending a dissertation titled "Rapid, scalable, amplified RNA detection in situ with clampFISH 2.0" on July 21, 2022, in Arjun Raj's lab, according to the Penn Engineering events calendar. That same year he was first author on a Nature Methods paper describing clampFISH 2.0, a method for detecting many RNA species at once in cells and tissue sections with amplified signal. He also spent time in the Bioscience Enterprise program at Cambridge, according to a 2024 profile from Hiretop.
Li's PhD work, per the same Hiretop profile, focused on genetics, epigenetics and next generation sequencing. Before Biocartesian she worked in business development at Imvaria, a company building AI tools for pulmonary fibrosis diagnosis. At Biocartesian she holds the chief science officer title, according to an April 2026 item describing the company's participation in a Philadelphia accelerator program. Other sources, including Tracxn, describe Li as chief executive, which does not match that CSO description.
The company's own words on why they started it, from the 2024 launch post: "We're Ian and Jess, two former UPenn PhDs on a mission to see every molecule in biological specimens. We've spent years advancing and troubleshooting the latest tools in biology, from DNA sequencing to microscopy, but even with these efforts, these tools revealed only a fraction of the underlying biology."
A Y Combinator company with two addresses
Biocartesian went through Y Combinator's Summer 2024 batch, the only funding source Y Combinator itself and the aggregator Extruct list for the company. From there the public record splits. Y Combinator, the company's own website, GetLatka and PitchBook all list Biocartesian's headquarters as San Francisco. Tracxn lists Philadelphia. In April 2026 the University City Science Center, a Philadelphia based nonprofit, named Biocartesian, listed simply as "Biocartesian (Philadelphia, PA)," to the eleventh cohort of its Capital Readiness Program, a five day, non equity bootcamp on fundraising and governance for early health tech founders. The company's current website lists a Philadelphia area code, 267, as its contact number. No source explains the discrepancy, and it is possible the company operates in both cities.
PitchBook and Tracxn both put total funding at $500,000, though they describe it differently. PitchBook lists it as two separate events, an accelerator allocation in January 2024 and an angel check from a group called Bullock Capital in August 2025. Tracxn describes a single seed round in 2024. GetLatka, a third data firm, reports no funding information for Biocartesian at all. None of the three is a primary filing, and a search of SEC EDGAR's full text index for "biocartesian" as of September 25, 2026 returned no Form D or other filing under that name.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Headquarters | Company site, Y Combinator, GetLatka and PitchBook list San Francisco. Tracxn and an April 2026 University City Science Center press release list Philadelphia, matching the company's Philadelphia area code phone number. | Differs across records |
| Underlying chemistry | ClampFISH 2.0, an amplified in situ RNA detection method, published in Nature Methods in 2022 with co-founder Ian Dardani as first author, from his UPenn dissertation work in Arjun Raj's lab. ARADIA, the company's current product, extends amplified in situ detection from RNA to DNA barcodes. | Public record |
| Y Combinator backing | Confirmed Summer 2024 batch company on Y Combinator's own site. YC is the only investor Y Combinator and Extruct list. | Public record |
| Total funding | PitchBook and Tracxn both report $500,000 raised, but describe it as different events, an accelerator allocation plus a 2025 angel check versus a single 2024 seed round. GetLatka reports no funding data. No SEC Form D found under the company's name as of Sep 25, 2026. | Aggregators disagree |
| FDA, trial and federal grant records | No FDA 510(k) or PMA filing, no registered clinical trial, no NIH award and no NSF award tied to Biocartesian found as of September 2026. | Not found |
| Named customers | Company materials describe customers only generically, as discovery teams or pharma research teams. No specific pharma or biotech customer name found in company statements or press coverage. | Not found |
| Revenue | GetLatka estimates about $330,000 in 2025 revenue, describing the figure as its own estimate rather than a company disclosure. | Third party estimate |
Read plainly: the science that underlies ARADIA traces to a real, peer-reviewed method its co-founder published before the company existed, and the Y Combinator backing is a matter of public record. Where the company operates, how much it has raised, and who is paying for its service are all points where the available sources either disagree or say nothing at all.
What to watch
- Whether the company settles its headquarters in one city; the Philadelphia listing is recent, dated April 2026, and could reflect an expansion rather than a correction.
- A Form D or other SEC filing that would put a primary source behind the $500,000 figure the aggregators report.
- Any named pharma or biotech customer, which none of the sources reviewed here provide.
- A peer-reviewed publication or preprint describing ARADIA itself, as opposed to the RNA method it builds on.
In their words
“We're Ian and Jess, two former UPenn PhDs on a mission to see every molecule in biological specimens.”
Biocartesian, Y Combinator launch post, August 2024 · Company
“Most diseases remain a mystery because existing methods can see less than 1% of the molecules within a biological specimen.”
Biocartesian, Y Combinator launch post, August 2024 · Company
“To use our technology, scientists simply ship their biological specimens to our laboratory, where we automate their conversion into digital molecular maps.”
Biocartesian, Y Combinator launch post, August 2024 · Company
“Imagine if we could see into the ~500 million existing tumor specimens to decode these cancers.”
Biocartesian, Y Combinator launch post, August 2024 · Company
“With ARADIA, genomic DNA targets can now be directly sequenced within cells, enabling pooled screens of CRISPR guides, CARs, UTRs, or engineered barcodes for morphological, protein, RNA, spatial, or live-cell phenotypes.”
Biocartesian company website, accessed September 2026 · Company
“Each cell is a data-rich experiment.”
Biocartesian company website, accessed September 2026 · Company
Related companies
Sources
- CompanyBiocartesian company page
- CompanyLaunch YC: Biocartesian, Converting biology into digital molecular maps
- CompanyBiocartesian company website
- IndependentBiocartesian: Innovating the Study of Disease
- IndependentBiocartesian company profile
- IndependentBiocartesian Funding, Complete Analysis
- IndependentBiocartesian Revenue 2025, $330K Est. ARR
- IndependentBiocartesian 2026 Company Profile, Valuation, Funding and Investors
- IndependentBiocartesian jobs and careers, aggregated company research page
- IndependentScience Center Announces 10 Startups Selected for Cohort 11 of its Capital Readiness Program
- Public recordClampFISH 2.0 enables rapid, scalable amplified RNA detection in situ
- Public recordBE Doctoral Dissertation, Rapid, scalable, amplified RNA detection in situ with clampFISH 2.0 (Ian Dardani)
- Public recordSEC EDGAR full text search for “biocartesian,” Form D, no results
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
